Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1962 1
1976 3
1977 1
1978 1
1979 1
1981 2
1983 1
1984 1
1985 1
1986 2
1988 1
1989 1
1990 2
1991 1
1992 8
1993 2
1994 3
1995 1
1998 4
1999 5
2000 4
2001 4
2003 5
2004 5
2005 4
2006 2
2007 2
2008 6
2009 5
2010 6
2011 8
2012 7
2013 4
2014 5
2015 7
2016 11
2017 10
2018 14
2019 12
2020 15
2021 11
2022 19
2023 13
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, Gupta N, Cheung WY, Pandey RM, Sharma A, Batra A. Santhosh A, et al. Trials. 2022 May 19;23(1):420. doi: 10.1186/s13063-022-06353-2. Trials. 2022. PMID: 35590388 Free PMC article. Clinical Trial.
INTRODUCTION: Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy. ...To date, there have been a lot of trials for hand-foot syndrome prevention using agents like pyridoxine, vitamin E, carvedilol, and various polyherbal formulations, …
INTRODUCTION: Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy. ...To date, there have been a lot o …
TORCH infections.
Neu N, Duchon J, Zachariah P. Neu N, et al. Clin Perinatol. 2015 Mar;42(1):77-103, viii. doi: 10.1016/j.clp.2014.11.001. Epub 2014 Dec 20. Clin Perinatol. 2015. PMID: 25677998 Review.
TORCH infections classically comprise toxoplasmosis, Treponema pallidum, rubella, cytomegalovirus, herpesvirus, hepatitis viruses, human immunodeficiency virus, and other infections, such as varicella, parvovirus B19, and enteroviruses. The epidemiology of these infections …
TORCH infections classically comprise toxoplasmosis, Treponema pallidum, rubella, cytomegalovirus, herpesvirus, hepatitis viruses, hu …
TORCH Congenital Syndrome Infections in Central America's Northern Triangle.
Lynn MK, Aquino MSR, Self SCW, Kanyangarara M, Campbell BA, Nolan MS. Lynn MK, et al. Microorganisms. 2023 Jan 19;11(2):257. doi: 10.3390/microorganisms11020257. Microorganisms. 2023. PMID: 36838223 Free PMC article.
TORCH pathogens are a group of globally prevalent infectious agents that may cross the placental barrier, causing severe negative sequalae in neonates, including fetal death and lifelong morbidity. ...Neonatal disorders and congenital birth defects are the leading causes o …
TORCH pathogens are a group of globally prevalent infectious agents that may cross the placental barrier, causing severe negative seq …
TORCH syndrome and TORCH screening.
[No authors listed] [No authors listed] Lancet. 1990 Jun 30;335(8705):1559-61. Lancet. 1990. PMID: 1972489 Review. No abstract available.
TORCH syndrome.
Epps RE, Pittelkow MR, Su WP. Epps RE, et al. Semin Dermatol. 1995 Jun;14(2):179-86. doi: 10.1016/s1085-5629(05)80016-1. Semin Dermatol. 1995. PMID: 7640200
The original TORCH complex described clinically similar congenital infections caused by Toxoplasma gondii, rubella virus, cytomegalovirus, and herpes simplex virus, types 1 and 2. ...
The original TORCH complex described clinically similar congenital infections caused by Toxoplasma gondii, rubella virus, cytomegalov …
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, Pramanik R, Gogia A, Prasad CP, Sehgal T, Gund S, Dev A, Cheung WY, Pandey RM, Kumar S, Gupta I, Batra A; D-TORCH Trial Investigators. Santhosh A, et al. J Clin Oncol. 2024 May 20;42(15):1821-1829. doi: 10.1200/JCO.23.01730. Epub 2024 Feb 27. J Clin Oncol. 2024. PMID: 38412399 Clinical Trial.
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. ...
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase …
The "torch syndrome.
Shin YH, Glass L, Evans HE. Shin YH, et al. Pediatr Ann. 1976 Feb;5(2):106-13. doi: 10.3928/0090-4481-19760201-11. Pediatr Ann. 1976. PMID: 177938 No abstract available.
The TORCH syndrome: a clinical review.
Fine JD, Arndt KA. Fine JD, et al. J Am Acad Dermatol. 1985 Apr;12(4):697-706. doi: 10.1016/s0190-9622(85)70095-3. J Am Acad Dermatol. 1985. PMID: 2985660 Review.
Several infections contracted in utero result in similar physical and laboratory findings during the neonatal period; the TORCH syndrome encompasses such patients. Skin lesions are a frequent finding and the dermatologist may play an important role in the early eval …
Several infections contracted in utero result in similar physical and laboratory findings during the neonatal period; the TORCH sy …
Congenital and perinatal infections.
Ostrander B, Bale JF. Ostrander B, et al. Handb Clin Neurol. 2019;162:133-153. doi: 10.1016/B978-0-444-64029-1.00006-0. Handb Clin Neurol. 2019. PMID: 31324308 Review.
Although congenital rubella syndrome has been eliminated in the Americas by immunization, several pathogens discussed in this chapter cannot currently be prevented by vaccines or effectively treated with the available antimicrobial drugs. ...As emphasized by the persisting …
Although congenital rubella syndrome has been eliminated in the Americas by immunization, several pathogens discussed in this chapter …
[TORCH syndrome].
Hidaka Y, Hara T. Hidaka Y, et al. Ryoikibetsu Shokogun Shirizu. 1999;(25 Pt 3):85-8. Ryoikibetsu Shokogun Shirizu. 1999. PMID: 10337745 Review. Japanese. No abstract available.
217 results